Skip to main content

Table 5 Lifetime costs, life-years, QALYs and incremental cost-effectiveness per true case of diabetes diagnosed

From: Cost-effectiveness of a national population-based screening program for type 2 diabetes: the Brazil experience

  Cost (US$) (discounted) Health outcomes (discounted) Incremental cost-effectiveness ratio
Cost of treatment Cost of complications Cost of screening Costs of intensified glycemic and hypertension control Total costs Remaining QALYs Total cost/QALY (US$)
No screening 3015 911 0 344.967 4271 4.6436  
Screening 3308 888 35.965 528.104 4760 4.6593  
Incremental 292.378 −22.478 36.965 183.137 489 0.0157 31,147
  1. Brazilian nationwide population screening program for diabetes, 2001